Skip to content
POM-V Prescription Required Companion Animal

Buprefelican Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Buprenorphine

Form

Injection

Species

Cats Dogs

Manufacturer

Le Vet Beheer B.V.

VMD MA No.

41821/3020

What it's used for

Post-operative analgesia in the dog and cat. Potentiation of the sedative effects of centrally acting agents in the dog.

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Buprenorphine

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Buprefelican Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Post-operative analgesia in the dog and cat.
Potentiation of the sedative effects of centrally acting agents in the dog.
For intramuscular or intravenous use.
DOG: Post-operative analgesia, potentiation of the sedation
10 - 20 µg/kg (0.3 - 0.6 ml per 10 kg)
CAT: Post-operative analgesia
10 - 20 µg/kg (0.3 - 0.6 ml per 10 kg)
For further pain relief the dose may be repeated if necessary:
DOG: either after 3 - 4 hours with 10 µg/kg (0.3 ml per 10 kg)
or after 5 - 6 hours with 20 µg/kg (0.6 ml per 10 kg)
CAT: Once, after 1 - 2 hours with 10-20 µg/kg (0.3-0.6 ml per 10 kg)
While sedative effects are present by 15 minutes after administration, analgesic
activity becomes apparent after approximately 30 minutes. To ensure that analgesia
is present during surgery and immediately on recovery, the product should be
administered preoperatively as part of premedication.
When administered for potentiation of sedation or as part of premedication, the dose
of other centrally-acting agents, such as acepromazine or medetomidine, should be
reduced. The reduction will depend on the degree of sedation required, the individual
animal, the type of other agents included in premedication and how anaesthesia is to

Revised: December 2020
AN: 00244/2020
be induced and maintained. It may also be possible to reduce the amount of
inhalational anaesthetic used.
Animals administered opioids possessing sedative and analgesic properties may
show variable responses. Therefore, the response of individual animals should be
monitored and subsequent doses should be adjusted accordingly. In some cases,
repeat doses may fail to provide additional analgesia. In these cases, consideration
should be given to using a suitable injectable NSAID.
An appropriately graduated syringe must be used to allow accurate dosing. The
closure must not be punctured more than 100 times (with a 21G or 23G needle).
Do not administer by the intrathecal or peridural route.
Do not use pre-operatively for Caesarean section (see section 4.7).
Do not use in known cases of hypersensitivity to the active substance or any of the
excipients.
Salivation, bradycardia, hypothermia, agitation, dehydration and miosis can occur in
the dog, and rarely hypertension and tachycardia.
Mydriasis and signs of euphoria (excessive purring, pacing, rubbing) commonly occur
in cats and will usually resolve within 24 hours.
Buprenorphine may cause respiratory depression (refer to section 4.5). When used to
provide analgesia, sedation is rarely seen, but may occur at dose levels higher than
those recommended.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
None.

Special precautions for use in animals
Buprenorphine may cause respiratory depression and as with other opioid drugs,
care should be taken when treating animals with impaired respiratory function or
animals that are receiving drugs that can cause respiratory depression.
In case of renal, cardiac or hepatic dysfunction or shock, there may be greater risk
associated with the use of the product. Safety has not been fully evaluated in
clinically compromised cats.

Revised: December 2020
AN: 00244/2020
Buprenorphine should be used with caution in animals with impaired liver function,
especially biliary tract disease, as the substance is metabolised by the liver and its
intensity and duration of action may be affected in such animals.
The safety of buprenorphine has not been demonstrated in animals less than 7
weeks of age.
Repeat administration earlier than the recommended repeat interval suggested in
section 4.9 is not recommended.
Long-term safety of buprenorphine in cats has not been investigated beyond 5
consecutive days of administration.
The effect of an opioid on head injury is dependent on the type and severity of the
injury and the respiratory support supplied.
Use of the product in the above circumstances should only be in accordance with the
benefit/risk assessment by the responsible veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
As buprenorphine has opioid-like activity, care should be taken to avoid self-injection.
In case of accidental self-injection or ingestion, seek medical advice immediately and
show the package leaflet or the label to the physician. Following eye contamination or
skin contact, wash thoroughly with cold running water. Seek medical advice if
irritation persists.
Naloxone should be available in case of accidental self-injection.
People with known hypersensitivity to the active substance or to the excipients
should avoid contact with the veterinary medicinal product.
Buprenorphine may cause some drowsiness, which may be potentiated by other
centrally acting agents, including tranquillisers, sedatives and hypnotics.
There is evidence in humans to indicate that therapeutic doses of buprenorphine do
not reduce the analgesic efficacy of standard doses of an opioid agonist, and that
when buprenorphine is employed within the normal therapeutic range, standard
doses of opioid agonist may be administered before the effects of the former have
ended without compromising analgesia. However, it is recommended that
buprenorphine is not used in conjunction with morphine or other opioid-type
analgesics, e.g. etorphine, fentanyl, pethidine, methadone, papaveretum or
butorphanol.
Buprenorphine has been used with acepromazine, alphaxalone/alphadalone,
atropine, dexmedetomidine, halothane, isoflurane, ketamine, medetomidine, propofol,
sevoflurane, thiopental and xylazine. When used in combination with sedatives,
depressive effects on heart rate and respiration may be augmented.
This veterinary medicinal product does not require any special storage conditions.
Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.